Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostate Adenocarcinoma × PROSTVAC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10 Prostate Adenocarcinoma 1 Metastatic Hormone-Sensitive Prostate Cancer 1

Interventions

Radiosurgery 4 Magnetic Resonance Spectroscopy 4 luprolide acetate gel depot 3 enzalutamide 3 Specimen Handling 2 Radiotherapy 2 Radiation 2 Leuprolide 2 Goserelin 2 Biopsy 2 relugolix 1 radium Ra 223 dichloride 1 niraparib 1 gallium 68 PSMA-11 1 fluciclovine F-18 1 entinostat 1 bicalutamide 1 atezolizumab 1 apalutamide 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abiraterone 1 X-Rays 1 Triptorelin Pamoate 1 Receptors, Bombesin 1 Radiotherapy, Image-Guided 1 Radiation Dose Hypofractionation 1 Proton Therapy 1 Prednisone 1 PROSTVAC 1 Neoadjuvant Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04020094 2021-09-22

AtezoVax

University of Utah

Phase 2 Withdrawn

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡